Grunhaus L, Dannon PN, Schreiber S, Dolberg OH, Amiaz R, Ziv R et al. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study. Biol Psychiatry 47: 314-324

Psychiatry Division, Sheba Medical Center, Ramat Gan, Israel.
Biological Psychiatry (Impact Factor: 10.26). 02/2000; 47(4):314-24. DOI: 10.1016/S0006-3223(99)00254-1
Source: PubMed


Repetitive transcranial magnetic stimulation (rTMS), a new method for the stimulation of the central nervous system, is being proposed as a potential new treatment in patients with major depressive disorder (MDD). We tested the hypothesis that rTMS would be as effective as electroconvulsive therapy (ECT) in patients with MDD.
Forty patients with MDD referred for ECT were randomly assigned to either ECT or rTMS. Repetitive transcranial magnetic stimulation was performed at 90% power of the motor threshold. The stimulation frequency was 10 Hz for either 2 sec (first eight patients) or 6 sec (final 12 patients) for 20 trains. Patients were treated for up to 20 treatment days. Electroconvulsive therapy was performed according to standard protocols.
Overall patients responded best to ECT (chi(2) = 3.8, p <.05). Patients with MDD and psychosis responded significantly better to ECT (chi(2) = 9.2, p <. 01), whereas MDD patients without psychosis responded similarly to both treatments (chi(2) = 0.0, ns). The analysis of variance with repeated measures of clinical variables for the whole sample revealed significant treatment effects for both groups; however, interaction between group and treatment was seen only for the Global Assessment of Function and the Sleep assessment. When the psychosis-nonpsychosis grouping was considered, patients with psychosis responded dramatically better to ECT in all assessments, whereas those without psychosis responded similarly to both treatments.
Overall ECT was a more potent treatment for patients with MDD, this being particularly evident in patients with MDD and psychosis; however, in patients with MDD without psychosis the effects of rTMS were similar to those of ECT. The results we report are encouraging and support an important role for rTMS in the treatment of severe MDD; however, additional blinded studies are needed to precisely define this role.

Download full-text


Available from: Shaul - Schreiber, Nov 01, 2014
1 Follower
17 Reads
  • Source
    • "ECT patients varied with respect to their psychopharmacological treatment, with two studies requiring that patients be off treatment before commencement of the study [29, 34]. In two other studies [20, 28], ECT was used as an add-on to the patient's psychotropic treatment, while patients undergoing rTMS were required to withdraw medications. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Electroconvulsive therapy (ECT) is the longest standing psychiatric treatment available and has unequivocal benefit in severe depression. However this treatment comes with a number of side effects such as memory impairment. On the other hand, Repetitive Transcranial Magnetic Stimulation (rTMS) is a relatively new form of treatment which has been shown to be efficacious in patients suffering from a number of psychopathologies, including severe depression, with few reported side effects. Due to its potential therapeutic efficacy and lack of side effects, rTMS has gained traction in the treatment of depression, with a number of authors keen to see it take over from ECT. However, it is not clear whether rTMS represents a therapeutic alternative to ECT. This meta-analysis will therefore compare the “gold standard” treatment for severe depression, with the relatively new but promising rTMS. A literature search will be performed with the intention to include all randomised clinical trials. The null hypothesis is that there is no difference in the antidepressant efficacy between the two types of treatment modalities. Statistical analysis of Hamilton Depression Rating Scale (HDRS) scores will be performed.
    Depression research and treatment 07/2014; 2014. DOI:10.1155/2014/135049
  • Source
    • "Of the available non-invasive therapeutic tools, repetitive transcranial magnetic stimulation (rTMS) had been shown to have various therapeutic effects on diseases, such as, depression, stroke, and acute and chronic pain (12-17). rTMS has also been reported to reduce central neuropathic pain after SCI, although its mechanism of action is unclear (18). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Spinal cord injury (SCI) causes not only loss of sensory and motor function below the level of injury but also chronic pain, which is difficult and challenging of the treatment. Repetitive transcranial magnetic stimulation (rTMS) to the motor cortex, of non-invasive therapeutic methods, has the motor and sensory consequences and modulates pain in SCI-patients. In the present study, we studied the effectiveness of rTMS and the relationship between the modulation of pain and the changes of neuroglial expression in the spinal cord using a rat SCI-induced pain model. Elevated expressions of Iba1 and GFAP, specific microglial and astrocyte markers, was respectively observed in dorsal and ventral horns at the L4 and L5 levels in SCI rats. But in SCI rats treated with 25 Hz rTMS for 8 weeks, these expressions were significantly reduced by about 30%. Our finding suggests that this attenuation of activation by rTMS is related to pain modulation after SCI. Therefore, rTMS might provide an alternative means of attenuating neuropathic pain below the level of SCI.
    Journal of Korean medical science 02/2013; 28(2):295-9. DOI:10.3346/jkms.2013.28.2.295 · 1.27 Impact Factor
  • Source
    • "Other positive predictors of improvement with rTMS include short duration of the current episode (Brakemeier et al., 2007; Lisanby et al., 2009), a high level of sleep disturbances (Brakemeier et al., 2007), female gender, absence of a co-morbid anxiety disorder and a higher baseline depression severity (Lisanby et al., 2009; Rossini et al., 2010). Conversely, presence of personality disorder (Fitzgerald and Daskalakis, 2011) and psychotic symptoms (Grunhaus et al., 2000) have been linked to inferior rTMS outcome. Neuropsychological assessments are often included in clinical trials of rTMS efficacy to monitor the safety of the technique. "
    [Show abstract] [Hide abstract]
    ABSTRACT: As the prevalence of treatment resistant depression (TRD) continues to rise, it remains a clinically important issue to identify neurobiological-, patient- and treatment-related factors that could potentially predict response to treatment. Medial temporal lobe (MTL) structures, in particular the hippocampus and amygdala have been implicated in inferior treatment response. The role of related structures such as the entorhinal cortex and the impact of MTL abnormalities on neurocognitive function, however, have not been systematically examined. The current study investigated MTL abnormalities and neurocognitive characteristics of eventual treatment responders and non-responders to a course of repetitive transcranial magnetic stimulation (rTMS) in order to identify potential predictors of treatment outcome. Prior to rTMS treatment all patients underwent magnetic resonance imaging (MRI) and neuropsychological assessment. MRI analysis was conducted using FreeSurfer 5.0. There was a 50% response rate following up to a 6-week course of daily rTMS treatments. Treatment response was defined as 50% reduction in Hamilton Depression Rating Scale and BDI-II scores from baseline. There was no difference in pre-treatment neurocognitive profiles and MTL volumes between eventual treatment responders and non-responders. Smaller pre-treatment left hippocampus volume showed a trend towards predicting eventual subjective improvement in depressive symptomatology. Although preliminary, our findings suggest that structural abnormalities may have some potential for predicting outcome to rTMS.
    Psychiatry Research 05/2012; 202(1):12-9. DOI:10.1016/j.pscychresns.2012.02.004 · 2.47 Impact Factor
Show more